October 27, 2016 (LIVERPOOL, ENGLAND) – TB Alliance, a non-profit organization dedicated to developing better and faster cures for tuberculosis (TB), today announced a unique collaboration with food and beverage company PepsiCo designed to improve the treatment for children with TB.  Many of today’s TB treatments are very bitter or unpleasant in taste, which when compounded with the long duration of treatment for TB, can lead to low tolerance and poor compliance – especially among children. 

New products expected to improve treatment and child survival from TB; Starting October 1 all children in Kenya initiated on TB treatment will be given the improved formulation.

The Global Alliance for TB Drug Development (TB Alliance) is seeking applications for the community representative to its Stakeholders Association.

UNIVERSITY PARK, Pa., June 27, 2016 -- A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).

NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced that they have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB). The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases.

NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum of Understanding outlining a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low-and middle-income countries. The two organisations will work together on a range of initiatives, with a focus on public health-oriented licensing strategies and the sharing of intellectual property to spur research and development of affordable new TB treatments.

More investment is needed to expand the portfolio of new TB drug candidates.

January 4, 2016 - TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD) Phase 1 study. This action has prompted the United States Food and Drug Administration (FDA) to place the organization’s Investigational New Drug (IND) submission for TBA-354 on clinical hold. TBA-354, which had entered Phase 1 testing in early 2015, is from the nitroimidazole class of chemicals.

The petition will be open for signatures until World TB Day, March 2016, when it will be presented to world leaders.

Medication simplifies and improves treatment for 1 million children with TB; Medicines come in dispersible fixed-dose combinations at the correct dosages, tablets no longer need to be cut or crushed; These products can improve adherence and child survival from TB.